SCHEMBL5769848

SCHEMBL5769848

CCc1cc2c(O)cccc2[nH]1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DAO P14920 4/20 0.50
DDO Q99489 3/20 0.50
IMPDH2 P12268 1/20 0.43
IMPDH1 P20839 1/20 0.43
PARP1 P09874 1/20 0.42
HRH4 Q9H3N8 1/20 0.42
MTNR1A P48039 4/20 0.40
MTNR1B P49286 4/20 0.40
IDO1 P14902 1/20 0.40
KIF11 P52732 1/20 0.40
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
RHEB Q15382 1/20 0.37
AR P10275 1/20 0.37
CTSV O60911 2/20 0.36
CTSL P07711 2/20 0.36
NPEPPS P55786 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8088130 0.86 CTSV (0.44) DAODDOIMPDH2IMPDH1PARP1
SCHEMBL5768535 0.83 RHEB (0.51) DAODDOIMPDH2IMPDH1HRH4
SCHEMBL28352953 0.81 IMPDH2 (0.43) DAODDOIMPDH2IMPDH1HRH4
SCHEMBL9587971 0.81 ASH1L (0.44) DAODDOIMPDH2IMPDH1HRH4
SCHEMBL20125059 0.79 DAO (0.60) DAODDOPARP1MTNR1AMTNR1B
SCHEMBL5771112 0.79 HTR1A (0.51) DAODDOIMPDH2IMPDH1HRH4
SCHEMBL30120739 0.79 HTR2C (0.45) DAODDOIMPDH2IMPDH1HRH4
SCHEMBL23714709 0.78 PARP1 (0.42) DAODDOPARP1HRH4MTNR1A
SCHEMBL17345632 0.78 DAO (0.49) DAODDOPARP1HRH4MTNR1A
SCHEMBL5917425 0.78 DAO (0.49) DAODDOPARP1HRH4MTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220400673-A1 METHODS FOR WEED GROWTH CONTROL Mustgrow Biologics Corp. (CA) 2022-12-22 US disclosed
WO-2022109755-A1 METHODS FOR CONTROLLING FUSARIUM WILT OF BANANA PLANTS Mustgrow Biologics Corp. (CA) 2022-06-02 WO disclosed
WO-2022082311-A1 METHODS AND COMPOSITIONS COMPRISING HERBICIDALLY ACTIVE COMPOUNDS AND THIOCYANATE COMPOUNDS FOR CONTROLLING WEED GROWTH Mustgrow Biologics Corp. (CA) 2022-04-28 WO disclosed
WO-2021077214-A1 METHODS FOR WEED GROWTH CONTROL Mustgrow Biologics Corp. (CA) 2021-04-29 WO disclosed
WO-2018069863-A1 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-04-19 WO disclosed
CN-101838232-B Preparation method for varespladib AISI MEDICAL TECHNOLOGY (NANJING) CO., LTD. (CN) 2012-02-22 CN disclosed
CN-101838232-A Preparation method for varespladib ACESYS PHARMATECH NANJING CO LTD 2010-09-22 CN disclosed
EP-1509515-A4 SUBSTITUTED 4-ARYL-4H-PYRROLO 2,3-H CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA INC (US) 2006-07-05 EP disclosed
EP-1509515-A2 SUBSTITUTED 4-ARYL-4H-PYRROLO 2,3-H CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF Cytovia, Inc. (US) 2005-03-02 EP disclosed
WO-2003097806-A2 SUBSTITUTED 4-ARYL-4H-PYRROLO[2,3-H]CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA, INC. (US) 2003-11-27 WO disclosed
CN-1067054-C 1H-indole-3-glyoxylamide spla2 inhibitors LILLY CO ELI (US) 2001-06-13 CN disclosed
WO-2000061554-A1 1-AMINO ETHYLINDOLE DERIVATIVES FOR THE TREATMENT OF URINARY INCONTINENCE SANOFI-SYNTHELABO (FR) 2000-10-19 WO disclosed
WO-2000061553-A1 2-AMINOETHYL-INDOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE SANOFI-SYNTHELABO (FR) 2000-10-19 WO disclosed
US-5254595-A Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them ELF SANOFI (FR) 1993-10-19 US disclosed
EP-0375560-B1 ARYLOXYPROPANOLAMINOTETRALINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME ELF SANOFI (FR) 1993-05-12 EP disclosed
EP-0375560-A1 Aryloxypropanolaminotetralines, process for their preparation and pharmaceutical compositions containing same ELF SANOFI (FR) 1990-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220400673-A1 METHODS FOR WEED GROWTH CONTROL TST, NOTUM, GLO1 DAO 602/4885DDO 1574/4885IMPDH2 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.